Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.95 |
| ▸ | ARG2 | P78540 | 4/20 | 0.57 |
| ▸ | ARG1 | P05089 | 3/20 | 0.57 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 3/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL8039436 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL30915820 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1219468 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1221228 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1220993 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL318676 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL3823204 | 0.98 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL8046798 | 0.98 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL296372 | 0.98 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL11904964 | 0.98 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110205294-B | Application of primary astrocyte/primary midbrain ventral neuron co-culture system in research on iron metabolism between astrocyte and neuron | 青岛大学 | 2021-05-28 | — | — | CN | disclosed |
| US-20190083407-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | GRUNENTHAL GMBH (DE) | 2019-03-21 | — | — | US | disclosed |
| US-10093691-B2 | Crystallization method and bioavailability | GRUNENTHAL GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| EP-3362071-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Grünenthal GmbH (DE) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017049294-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170022227-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20160016982-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9169279-B2 | Crystallization method and bioavailability | THAR PHARMACEUTICALS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| WO-2014159811-A1 | SALTS AND POLYMORPHS OF A COMPOUND | OLIVER PATRICIA (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20130035315-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMA, LLC | 2013-02-07 | — | — | US | disclosed |
| US-6054448-A | TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM. | ELI LILLY AND COMPANY LIMITED (GB) | 2000-04-25 | — | — | US | disclosed |
| EP-0973936-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| CN-1234039-A | 3-mercaptoacetylamino-1, 5-disubstituted-2-oxo-azepane derivatives as matrix metalloproteinase inhibitors | HOECHST MARION ROUSSEL INC (US) | 1999-11-03 | — | — | CN | disclosed |
| EP-0928291-A1 | 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-14 | — | — | EP | disclosed |
| WO-1998046786-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5808069-A | Salts of 2-(3-benzoylphenyl) propionic acid with organic bases and pharmaceutical compositions thereof | DOMPE' FARMACEUTICI SPA (IT) | 1998-09-15 | — | — | US | disclosed |
| EP-0837061-A1 | Pharmaceutical acidic compounds | ELI LILLY AND COMPANY LIMITED (GB) | 1998-04-22 | — | — | EP | disclosed |
| WO-1998012211-A1 | 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | HOECHST MARION ROUSSEL, INC. (US) | 1998-03-26 | — | — | WO | disclosed |
| EP-0703893-A1 | SALTS OF 2-(3-BENZOYLPHENYL) PROPIONIC ACID WITH ACHIRAL AND CHIRAL ORGANIC BASES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DOMPE FARMACEUTICI S.P.A. (IT) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994020449-A1 | SALTS OF 2-(3-BENZOYLPHENYL)PROPIONIC ACID WITH ACHIRAL AND CHIRAL ORGANIC BASES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DOMPE'FARMACEUTICI SPA (IT) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016982-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | ABCG2, GYS2, PYGL | GSR 2522/4885ARG2 4444/4885ARG1 4237/4885 |
| US-20130035315-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | ABCG2, GYS2, PYGL | GSR 2522/4885ARG2 4444/4885ARG1 4237/4885 |
| US-10093691-B2 | Crystallization method and bioavailability | ABCG2, GYS2, PYGL | GSR 2522/4885ARG2 4444/4885ARG1 4237/4885 |
| US-20190083407-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | ABCG2, GYS2, PYGL | GSR 2522/4885ARG2 4444/4885ARG1 4237/4885 |
| US-20170022227-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | ABCG2, GYS2, PYGL | GSR 2522/4885ARG2 4444/4885ARG1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.